Phase 3 Readout~month

Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following

Name: Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following
Start: 2026-09-01

September 1, 2026

Company: RenovoRx, Inc. (RNXT)
Drug: sequential
Indication: Locally Advanced Pancreatic Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following — RNXT Phase 3 Readout | BioSniper